ANNX
Annexon, Inc.
NASDAQ · Healthcare · Biotechnology · US
$4.87
+0.62%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−3.7x
Market Cap
$923.25M
MomentumView details →
1D Return
+0.62%
YTD Return
−3.78%
RSI (14)
40.6
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−3.7x
Market Cap
$923.25M
RSI (14)
40.6
MomentumView details →
1D Return
+0.62%
YTD Return
−3.78%
SummaryUpdated Jun 1, 2026
Annexon, Inc. (NASDAQ:ANNX) is a clinical-stage biopharmaceutical company founded in 2011 and headquartered in Brisbane, California. The company went public in July 2020 and focuses on discovering and developing novel therapeutics that target the complement system, a critical component of the immune system. Annexon's approach centers on inhibiting C1q, the initiating molecule of the classical complement pathway, to treat autoimmune, neurodegenerative, and ophthalmic disorders where excessive complement activation contributes to disease progression.
Similar companies
Latest newsMore news →
Annexon announced the launch of an open-label extension study of vonaprument for geographic atrophy, and added a Month 24 dual primary endpoint to its Phase 3 ARCHER II trial.24d agoAnnexon, Inc. reported its Q2 2026 financial results, with a net loss of $55.3 million and diluted EPS of -$0.28, and cash and investments of $209.2 million as of June 30, 2026.24d ago